Keskeiset käsitteet
Bacterial endocarditis can be a potential adverse effect following COVID-19 treatment.
Tiivistelmä
Abstract and Introduction:
- COVID-19 treatment choices and long-term complications are crucial.
- Bacterial endocarditis is rare but significant post-SARS-CoV-2 infection.
Case Presentation:
- Two cases of bacterial endocarditis post-COVID-19 treatment discussed.
- Both patients tested positive for PCR and were treated with tocilizumab and corticosteroids.
- MRSA detected in blood cultures, leading to confirmed endocarditis diagnosis.
- Patients underwent open-heart surgery and showed improvement with medication.
Conclusion:
- Secondary infections post-immunocompromising treatments can lead to serious conditions like infective endocarditis.
Tilastot
"Methicillin-resistant Staphylococcus aureus (MRSA) was detected in the blood cultures of both patients."
Lainaukset
"Adjacent to cardiovascular inclusion as COVID-19 disease complications, secondary infection taken after the organisation of immunocompromising specialists can result in basic maladies and conditions counting infective endocarditis."